Revisions to the General Safety Requirements for Biological Products

FederalRegulations

Ask Donna

How this section applies to your facts.

Federal Register › Vol. 63 › 63 FR 19399

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 610

[Docket No. 97N-0449]

RIN 0910-ZA08

Revisions to the General Safety Requirements for Biological

Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the

biologics regulations by adding ``cellular therapy products'' to the

list of products excepted from the general safety test (GST) and by

adding an administrative procedure for obtaining exemptions from the

GST requirements for other biological products. FDA is taking this

action because the GST may not be relevant or necessary for biological

products, including cellular therapy products, currently in various

stages of development. This direct final rule is part of FDA's

continuing effort to achieve the objectives of the President's

``Reinventing Government'' initiative, and is intended to reduce the

burden of unnecessary regulations on biological products without

diminishing the protection of the public health. Elsewhere in this

Federal Register, FDA is publishing a companion proposed rule under

FDA's usual procedures for notice and comment to provide a procedural

framework to finalize the rule in the event the agency receives any

significant adverse comment and withdraws this direct final rule.

DATES: This regulation is effective September 2, 1998. Submit written

comments on this direct final rule on or before July 6, 1998. Submit

written comments on the information collection provisions by June 19,

1998.

ADDRESSES: Submit written comments on the direct final rule to the

Dockets Management Branch (HFA-305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Dano B. Murphy, Center for Biologics

Evaluation and Research (HFM-630), Food and Drug Administration, 1401

Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-594-3074.

SUPPLEMENTARY INFORMATION:

I. Background

Under Sec. 610.11 (21 CFR 610.11), a test for general safety shall

be performed on biological products intended for administration to

humans. A GST is one of several tests in part 610, General Biological

Product Standards (21 CFR part 610), that are intended to help ensure

the safety, purity, and potency of biological products administered to

humans. The test is used to detect extraneous toxic contaminants that

may be present in a particular biological product. As outlined in

Sec. 610.11, an amount of the final container product is injected into

the peritoneum of guinea pigs and mice. The GST is satisfactory when:

The criteria in Sec. 610.11(d) are met, i.e., injected animals survive

the test period, they do not exhibit an unexpected or nonspecific

response that may indicate a difference in quality of the product, and

they weigh no less at the end of the test period than they did at the

time of injection. Section 610.11(g) identifies the biological products

for which the GST is not required.

The requirement for a GST test was originally intended as a means

by which harmful extraneous toxins could be detected (41 FR 10888,

March 15, 1976). The source of such toxins may be bacterial toxins that

persist even after the bacteria producing the toxins had been removed

by filtration or killed by sterilization, or formulation errors that

result in harmful levels of certain substances, e.g., preservatives.

The test continues to serve as a safety net to detect harmful

contaminants that may enter or be introduced into the final container

through undetected failures in the manufacture of biological products.

In the last 15 years, technological advances have increased the

ability of manufacturers to control and analyze the manufacture of many

biotechnology derived biological products. After more than a decade of

experience with these products, FDA found that it could evaluate many

aspects of a biological product's safety, purity, or potency with tests

other than those prescribed in part 610. In response to these

developments, FDA published in the Federal Register on May 14, 1996 (61

FR 24227), a final rule exempting certain biotechnology and synthetic

biological products from, among other things, specified regulations

applicable to biological products, including the GST (Sec. 601.2 (21

CFR 601.2)).

Recent scientific advances have dramatically increased the

diversity of biological products regulated under section 351 of the

Public Health Service Act. In particular, cellular-based therapies

intended for the diagnosis, cure, mitigation, treatment, or prevention

of disease in man have been the subject of much biomedical research and

are used with increasing frequency. Typically, cellular therapies use

autologous or allogeneic cells, often lymphocyte subpopulations, but

other cell types may be used, obtained from a donor and manipulated ex

vivo to varying degrees before use in the recipient patient. The ex

vivo manipulation may consist of, for example, growing a small number

of cells to increase their number (cellular expansion), selective

enrichment of a specific cell subpopulation, or the addition of

specific cell factors or genetic sequences. A common characteristic of

cellular therapies is the need for a relatively short turn-around time

between first obtaining the cells and their final infusion as a

cellular therapy product into the patient. In many cases, cells used in

the final cellular therapeutic are obtained only hours before they must

be used and turn-around times of several days or less are presently

typical. A test, such as the GST, that requires 7 days to complete is

not compatible with such products and such a requirement would make it

impossible to use many of these products. Furthermore, because the

procedures and materials used to produce cellular therapy products are

stringently controlled and monitored, the likelihood of an extraneous

toxic component contaminating a final product is greatly reduced.

In the Federal Register of June 3, 1994 (59 FR 28821 at 28822), FDA

announced that the Center for Biologics Evaluation and Research (CBER)

would review certain biologics regulations to identify regulations that

are outdated, burdensome, inefficient, duplicative, or otherwise

unsuitable or unnecessary. FDA included Sec. 610.11 in the review. On

January 26, 1995, FDA held a public meeting to discuss the

retrospective review of regulations applicable to biological products

and to provide a forum for the public to voice its comments regarding

the retrospective review. At the meeting, only one comment addressed

whether Sec. 610.11 should be retained unchanged, modified, or deleted.

The comment acknowledged the utility of the GST for products that have

a high degree of intrinsic variability. However, despite its recognized

value in some specific cases, the comment questioned the rationale for

requiring the GST for all biological products intended for

administration to humans. The comment noted that the amount of final

container product administered to animals for the GST may not have any

correlation with the human dose, that some biological products possess

extensive documented histories of no GST failure, and that each run of

the test requires the use of at least four animals. The comment

suggested that FDA revise Sec. 610.11 to grant exemptions from the GST

when the test is unnecessary to evaluate the safety of a specific

product.

FDA received several comments from the public regarding issues

raised at the January 26, 1995, meeting. Two comments agreed with the

suggestion made at the public meeting that Sec. 610.11 be amended to

include a provision that would allow certain products to be exempted

from the GST upon approval of the Director, CBER. Another comment

suggested that exemptions be permitted for appropriate biological

products by the Director, CBER, after a suitable qualification period

was met without any failure of the GST, such as 1 year of production or

after 10 consecutive production lots pass the GST. The comment

suggested that a demonstrated record of GST compliance also be

supported by well-documented in-

process safety controls, long-term compliance with current good

manufacturing practices regulations (21 CFR parts 210 and 211), and the

use of sophisticated analytical techniques capable of adequately

characterizing the final product and validating its safety.

On March 17, 1997, FDA held a public meeting to discuss the

agency's proposed approach to the regulation of human cellular and

tissue-based products. The meeting was attended by FDA, members of

industry, representatives from accrediting organizations, and

interested members of the public. During the meeting, two attendees

addressed the use of the GST with cellular therapy products. The

comments regarded the 7-day incubation time of the test as an

unworkable requirement for many cellular therapy products and suggested

that such products be exempted from the test, including allogeneic and

autologous cell therapy products.

II. Highlights of the Direct Final Rule

FDA agrees with the comments received that cellular therapy

products should be exempt from the GST requirement. FDA is issuing this

direct final rule to expand the exceptions in Sec. 610.11(g) to include

``cellular therapy products.'' In addition, FDA is adding an

administrative procedure for manufacturers of other biological products

to request and obtain exemptions from the GST. Many biological products

are currently manufactured, or will be manufactured in the future,

under highly controlled and rigorously monitored conditions. Therefore,

under the amended rule, manufacturers of biological products that

employ appropriate production controls and quality assurance safeguards

would be permitted to apply for an exemption from the GST requirement.

Such manufacturers will be required to provide supporting documentation

to the Director, CBER, as to why a product should not be subject to the

GST requirement. The request shall include an explanation of why the

GST is unnecessary or cannot be performed due to the mode of

administration, the method of preparation, or the special nature of the

product and shall describe alternate procedures, if any, to be

employed. The Director, CBER, may grant an exemption if she finds that

the manufacturer's submission justifies an exemption.

The value of the GST as a final assay for the presence of

extraneous toxins may be diminished for certain biological products,

such as vaccines containing recombinant or purified protein antigens.

Recombinant protein antigens are not produced from infectious bacteria

or virus and antigens derived from infectious pathogens may undergo

many production steps that kill or neutralize the pathogen or

inactivate toxic materials. Therefore, for these kinds of products, the

risk is extremely low that viable pathogenic or toxic materials will

persist through production to the final filling. The effectiveness of

such steps can be validated by specific in-process tests and controls

which can be used to alert manufacturers to potential problems. To

further reduce the possibility that an undetected extraneous toxin

could contaminate the product just before or during the final fill

stage, a manufacturer may use production facilities and final fill

equipment that can detect or enable the detection of any loss in the

integrity of the production and fill processes. In addition, a method

of production and detailed product characterization able to meet

requirements similar to those set out in Sec. 601.2(c) could be used to

demonstrate the safety, purity, and potency of a biological product

without the use of the GST. Each manufacturer will be responsible for

identifying the product or products that are produced in such a manner

that makes the GST unnecessary to ensure the safety, purity, and

potency of the biological product. Manufacturers wishing to obtain an

exemption to the GST for a particular product would contact the

appropriate product division of CBER for specific information regarding

how to apply and what information should be included in the application

or supplemental application.

III. Rulemaking Action

In the Federal Register of November 21, 1997 (62 FR 62466), FDA

described its procedures on when and how FDA will employ direct final

rulemaking. FDA believes that this rule is appropriate for direct final

rulemaking because FDA views this rule as a noncontroversial amendment

and anticipates no significant adverse comments. Consistent with FDA's

procedures on direct final rulemaking, FDA is publishing elsewhere in

this Federal Register issue, a companion proposed rule to amend the

existing GST rule. The companion proposed rule provides a procedural

framework within which the rule may be finalized in the event the

direct final rule is withdrawn because of any significant adverse

comment. The comment period for the direct final rule runs concurrently

with the companion proposed rule. Any comments received under the

companion proposed rule will be considered as comments regarding the

direct final rule.

FDA has provided a comment period on the direct final rule of 75

days after April 20, 1998. If the agency receives any significant

adverse comment, FDA intends to withdraw this direct final rule action

by publication in the Federal Register within 30 days after the comment

period ends. A significant adverse comment is defined as a comment that

explains why the rule would be inappropriate, including challenges to

the rule's underlying premise or approach, or would be ineffective or

unacceptable without a change. In determining whether a significant

adverse comment is sufficient to terminate a direct final rulemaking,

FDA will consider whether the comment raises an issue serious enough to

warrant a substantive response in a notice-and-comment process.

Comments that are frivolous, insubstantial, or outside the scope of the

rule will not be considered significant or adverse under this

procedure. For example, a comment requesting inclusion of additional

product classes in the exceptions paragraph of the GST (Sec. 610.11(g))

will not be considered a significant adverse comment because it is

outside the scope of this rule. A comment recommending a rule change in

addition to the rule would not be considered a significant adverse

comment, unless the comment states why the rule would be ineffective

without additional change. In addition, if a significant adverse

comment applies to part of a rule and that part can be severed form the

remainder of the rule, FDA may adopt as final those parts of the rule

that are not subject of a significant adverse comment.

If any significant adverse comment is received during the comment

period, FDA will publish, within 30 days after the comment period ends,

a document withdrawing the direct final rule. If FDA withdraws the

direct final rule, all comments received will be applied to the

proposed rule and will be considered in developing a final rule using

the usual Administrative Procedure Act notice-and-comment procedures.

If FDA receives no significant adverse comments during the

specified comment period, FDA intends to publish a confirmation

document within 30 days after the comment period ends confirming that

the direct final rule will go into effect on September 2, 1998.

IV. Analysis of Impacts

A. Review Under Executive Order 12866 and the Regulatory Flexibility

Act

FDA has examined the impact of the direct final rule under

Executive Order 12866, the Regulatory Flexibility Act (5 U.S.C. 601-

612), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4).

Executive Order 12866 directs agencies to assess all costs and benefits

of available regulatory alternatives and, when regulation is necessary,

to select regulatory approaches that maximize net benefits (including

potential economic, environmental, public health and safety, and other

advantages; distributive impact; and equity). The agency believes that

this direct final rule is consistent with the regulatory philosophy and

principles identified in the Executive Order. The direct final rule is

a significant regulatory action as defined by the Executive Order and

is subject to review under the Executive Order because it deals with a

novel policy issue.

In accordance with the principles of Executive Order 12866, the

result of the direct final rule will be a substantial reduction in

burdens on applicants filing for approval of certain biological

products

The Regulatory Flexibility Act requires agencies to analyze

regulatory options that would minimize any significant impact of a rule

on small business entities. Because, as stated previously, the overall

result of the direct final rule will be a substantial reduction of the

regulatory and reporting burdens, the agency certifies that the direct

final rule will not have a significant negative economic impact on a

substantial number of small entities. Therefore, under the Regulatory

Flexibility Act, no further analysis is required. This rule also does

not trigger the requirement for a written statement under section

202(a) of the Unfunded Mandates Reform Act because it does not impose a

mandate that results in an expenditure of $100 million or more by

State, local, and tribal governments in the aggregate, or by the

private sector in any one year.

B. Environmental Impact

The agency has determined under 21 CFR 25.31(j) that this action is

of a type that does not individually or cumulatively have a significant

effect on the human environment. Therefore, neither an environmental

assessment nor an environmental impact statement is required.

V. The Paperwork Reduction Act of 1995

This direct final rule contains information collection provisions

that are subject to review by the Office of Management and Budget (OMB)

under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The

title, description, and respondent description of the information

collection provisions are shown below with an estimate of the annual

reporting burden. Included in the estimate is the time for reviewing

the instructions, searching existing data sources, gathering and

maintaining the data needed, and completing and reviewing each

collection of information.

FDA invites comments on: (1) Whether the proposed collection of

information is necessary for the proper performance of FDA's functions,

including whether the information will have practical utility; (2) the

accuracy of FDA's estimate of the burden of the proposed collection of

information, including the validity of the methodology and assumptions

used; (3) ways to enhance the quality, utility, and clarity of the

information to be collected; and (4) ways to minimize the burden of the

collection of information on respondents, including through the use of

automated collection techniques, when appropriate, and other forms of

information technology.

Title: Requests for Exemptions from the General Safety Testing

Requirements for Biological Products.

Description: FDA is revising the requirements for general safety

testing (GST) set forth in Sec. 610.11. The test serves as a safety net

to detect harmful contaminants that may enter or be introduced into the

final container through undetected failures in the manufacture of

biological products. The revision would add ``cellular therapy

products'' to the list of products excepted from the GST, and add an

administrative procedure for obtaining exemptions from the GST

requirements for other biological products. FDA is proposing the new

administrative procedure because the GST may not be feasible or

appropriate for some biological products. FDA anticipates that

manufacturers requesting exemptions would have a demonstrated record of

GST compliance supported by long-term compliance with CGMP's, well-

documented in-process safety controls, and use sophisticated analytical

techniques to adequately characterize the final product and validate

its safety. Manufacturers would submit their request and documentation

to the Director, CBER, who may grant the exemption if it is determined

that the manufacturer's submission justifies an exemption.

Description of Respondents: Manufacturers of biological products.

The direct final rule would require only those manufacturers

requesting an exemption from the GST under Sec. 610.11(g)(2) to submit

additional information as part of a license application or supplement

to an approved license application. Manufacturers of ``cellular therapy

products'' would be excepted from the GST under Sec. 610.11(g)(1) and

thus, not have to submit an exemption request. In fact, manufacturers

of cellular therapy products would be relieved of significant burdens

because they would no longer be required to perform the GST and report

the results to FDA. FDA estimates that annually it will receive

approximately 10 requests for administrative exemption from the GST

under Sec. 610.11(g)(2). FDA estimates that 40 hours will be required

for an applicant to complete and submit the appropriate information for

the exemption request. Since that information is ordinarily compiled

and organized by the manufacturer while performing the GST, FDA

anticipates that the additional time needed to submit an exemption

request will be minimal.

Table 1.--Estimated Annual Reporting Burden1

----------------------------------------------------------------------------------------------------------------

Annual

21 CFR Section No. of Frequency per Total Annual Hours per Total Hours

Respondents Response Responses Response

----------------------------------------------------------------------------------------------------------------

610.11(g)(2) 10 1 10 40 400

Total 10 10 40 400

----------------------------------------------------------------------------------------------------------------

\1\ There are no capital costs or operating and maintenance costs associated with this collection of

information.

As provided in 5 CFR 1320.5(c)(1), collections of information in a

direct final rule are subject to the procedures set forth in 5 CFR

1320.10. Interested persons and organizations may submit comments on

the information collection requirements of this direct final rule by

June 19, 1998, to the Dockets Management Branch (HFA-305), Food and

Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

At the close of the 60-day comment period, FDA will review the

comments received, revise the information collection provisions as

necessary, and submit these provisions to OMB for review. FDA will

publish a notice in the Federal Register when the information

collection provisions are submitted to OMB, and an opportunity for

public comment to OMB will be provided at that time. Prior to the

effective date of the direct final rule, FDA will publish a notice in

the Federal Register of OMB's decision to approve, modify, or

disapprove the information collection provisions. An agency may not

conduct or sponsor, and a person is not required to respond to, a

collection of information unless it displays a currently valid OMB

control number.

VI. Request for Comments

Interested persons may, on or before July 6, 1998, submit to the

Docket Management Branch (address above) written comments regarding

this proposal. This comment period runs concurrently with the comment

period for the companion proposed rule. Two copies of any comments are

to be submitted, except that individuals may submit one copy. Comments

are to be identified with the docket number found in brackets in the

heading of this document. Received comments may be seen in the office

above between 9 a.m. and 4 p.m., Monday through Friday. All comments

received will be considered comments regarding the proposed rule and

this direct final rule. In the event the direct final rule is

withdrawn, all comments received regarding the companion proposed rule

and the direct final rule will be considered comments on the proposed

rule.

List of Subjects in 21 CFR Part 610

Biologics, Labeling, Reporting and recordkeeping requirements.

Therefore under the Federal Food, Drug, and Cosmetic Act, and under

authority delegated to the Commissioner of Food and Drugs, 21 CFR part

610 is amended as follows:

PART 610--GENERAL BIOLOGICAL PRODUCTS STANDARDS

1. The authority citation for 21 CFR part 610 continues to read as

follows:

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371; 42

U.S.C. 216, 262, 263, 263a, 264.

2. Section 610.11 is amended by revising paragraph (g) to read as

follows:

Sec. 610.11 General safety.

* * * * *

(g) Exceptions--(1) The test prescribed in this section need not be

performed for Whole Blood, Red Blood Cells, Cryoprecipitated AHF,

Platelets, Plasma, or Cellular Therapy Products.

(2) For products other than those identified in paragraph (g)(1) of

this section, a manufacturer may request from the Director, Center for

Biologics Evaluation and Research, an exemption from the general safety

test. The manufacturer shall submit information as part of a license

application submission or supplement to an approved license application

establishing that because of the mode of administration, the method of

preparation, or the special nature of the product a test of general

safety is unnecessary to assure the safety, purity, and potency of the

product or cannot be performed. The request shall include any alternate

procedures, if any, to be performed. The Director, Center for Biologics

Evaluation and Research, upon finding that the manufacturer's request

justifies an exemption, may exempt the product from the general safety

test subject to any condition necessary to assure the safety, purity,

and potency of the product.

Dated: April 10, 1998.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 98-10314 Filed 4-17-98; 8:45 am]

BILLING CODE 4160-01-F

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.